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Improved assessment of bone turnover by the PTH-(1-84)/ ondary to the loss of kidney function. These abnormali-
large C-PTH fragments ratio in ESRD patients. ties have a substantial impact on the morbidity and mor-
Background. The “intact” parathyroid hormone (PTH) tality of these patients. Despite an initially commonassay recognizes PTH-(1-84) as well as amino terminally trun-
pathogenetic pathway, there are no uniform histopatho-cated PTH fragments, that is, large carboxyterminal PTH frag-
logic changes among the patients. Patients on dialysisments (C-PTH fragments). The present study investigated
whether the use of the plasma PTH-(1-84)/C-PTH fragment present either with various degrees of secondary hyper-
ratio enhances the noninvasive assessment of bone turnover parathyroidism, with or without mineralization defect,
in patients on dialysis.
resulting in high or normal bone turnover or with ady-Methods. Bone biopsies and blood samples for determina-
namic bone characterized by low bone turnover. Distinc-tions of routine indices of bone turnover and PTH peptides
were obtained in 51 adult patients on dialysis not treated with tion between high or normal versus low bone turnover
drugs affecting bone such as vitamin D or corticosteroids. is essential because these entities require divergent ther-
Blood levels of large C-PTH fragments were calculated by
apeutic approaches, that is, indication for vitamin D andsubtracting PTH-(1-84) from “intact” PTH. Patients were clas-
level of dose aggressiveness, use of calcium- versus non–sified according to their levels of bone turnover based on histo-
morphometrically obtained results of activation frequency. calcium-containing phosphate binders, and choice of cal-
Prediction of bone turnover by the various blood indices was cium dialysate concentration. Currently, histologic anal-
done by using proper statistical methods. In addition, hypercal- ysis of bone after tetracycline labeling remains the gold
cemia was induced by calcium gluconate infusion in a subset
standard for assessment of bone turnover. However, thisof patients, and levels of PTH-(1-84), “intact” PTH, and PTH-
technique is not always available. Physicians generally(1-84)/C-PTH fragment ratio were determined.
Results. The PTH-(1-84)/C-PTH fragment ratio was the best rely on noninvasive methods, particularly on blood con-
predictor of bone turnover. A ratio 1 predicted high or nor- centrations of intact parathyroid hormone (PTH). How-
mal bone turnover (sensitivity 100%), whereas a ratio1 indi- ever, the level of blood PTH that predict low or high-cated a high probability (sensitivity 87.5%) of low bone turn-
normal bone turnover has not been clearly established.over. Calcium infusion resulted in decrease in PTH-(1-84)/
In the early 1990s, it was advocated that adequateC-PTH fragment ratio.
Conclusions. The PTH-(1-84)/C-PTH fragment ratio pre- control of secondary hyperparathyroidism, that is, nor-
dicts bone turnover with acceptable precision for biological mal bone turnover, is achieved when blood levels of
measurements. Moreover, a change in serum calcium levels is
intact PTH are between one and four times the upperone of the regulators of the relative amount of circulating PTH-
limit of normal range [1–5]. However, we and others(1-84) and its large C-PTH fragments.
found low bone turnover on bone histology in patients
on dialysis with intact PTH levels of approximately 10
Virtually all patients with end-stage renal disease times the upper limit of normal [6, 7]. Because various
(ESRD) develop mineral and bone abnormalities sec- degrees of superimposed bone aluminum accumulation
may have contributed to these discrepancies between
studies, we recently revisited the value of intact PTH
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levels for assessment of bone turnover in 157 patientssecondary hyperparathyroidism, carboxyterminal PTH fragments,
hypercalcemia, hormone radioimmunoassay. on dialysis (abstract; Monier-Faugere et al, J Am Soc
Nephrol 11:554A, 2000) [8]. These patients were given
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PTH levels100 pg/mL had low bone turnover, whereas 84)/C-PTH fragment ratio has more predictive power in
distinguishing low and high bone turnover than the use89.4% patients with levels 500 pg/mL had high or nor-
mal bone turnover. However, in the majority of the pa- of PTH-(1-84) alone.
The present study was undertaken (1) to test the pre-tients, that is, in patients with intact PTH between 100
and 500 pg/mL, low bone turnover was observed in 59% viously mentioned hypothesis and (2) to determine the
effects of hypercalcemia on the PTH-(1-84)/C-PTH.and high or normal in the remaining 41% of the patients.
The characteristics of the commercially available kits
for determinations of intact PTH may account, at least
METHODS
in part, for the relative poor predictability of intact PTH
Patientsin assessing bone turnover. Indeed, it has been demon-
strated that two immunoreactive components can be de- Patients were recruited prospectively from local dial-
ysis clinics during the years 1999 to 2000. The inclusiontected with available assays for intact PTH [9]. One com-
ponent comigrates with synthetic human PTH-(1-84), criteria were age above 18 years and willingness to un-
dergo a bone biopsy and blood drawing. The exclusionwhereas the other non-(1-84) component is more hydro-
philic and accumulates in renal failure, accounting for 40 criteria were a history of past or present treatment with
aluminum phosphate binders, treatment with calcitriolto 60% of the total immunoreactivity in ESRD patients
[9]. Subsequently, it was shown that the non-(1-84) PTH or medications known to affect bone metabolism (di-
phenylhydantoin, glucocorticoids, cyclosporine) duringmolecule comigrates closely with the synthetic human
7-84 PTH fragment [10]. Recently, a novel immunoradio- the last six months, systemic illnesses or organ diseases
other than diabetes that may affect bone metabolismmetric assay was developed that exclusively detects the
full-length 1-84 but not PTH fragments [11, 12]. Combin- (that is, gastrointestinal diseases, liver disease, malignan-
cies, tuberculosis, acquired immunodeficiency syndrome,ing the results employing this new PTH-(1-84) assay with
high-performance liquid chromatography (HPLC) pro- chronic alcoholism, drug addiction, failed transplant or
parathyroidectomy within the last six months, participa-files, it was demonstrated that the non-(1-84) PTH con-
sists of amino terminally truncated PTH fragments, that tion in other studies), or tetracycline allergy.
One hundred thirty-five patients were screened. Sixty-is, large carboxyterminal PTH fragments (C-PTH frag-
ments) [12], likely PTH-(7-84). five were eligible and 51 agreed to participate in the
study; informed consents were signed. There were 29The C-PTH fragments have long been considered in-
active peptides. However, it has been shown that they men and 22 women with a mean age of 47  3 and
43  3 years, respectively. Thirty-two patients were onregulate alkaline phosphatase, osteocalcin, collagen1(I),
and insulin growth factor binding protein-5 in rat and hemodialysis (HD), and 19 patients were on chronic
ambulatory peritoneal dialysis (CAPD). The mean dura-human osteoblast-like cells [13–16]. They also stimulate
the proliferation and activity of osteoclasts [17] and stim- tion on dialysis treatment was 25.6  3.0 months (2
months to 7 years). Underlying kidney diseases wereulate activity of hypertrophic chondrocytes [18, 19]. Also,
differences in the action of PTH-(1-84) and PTH-(1-34) hypertensive nephropathy (N  18), diabetes mellitus
(N 12), glomerulonephritis (N 8), interstitial nephri-on various cells have been noted [20–23], pointing to a
role of the C-PTH fragments in the activity of PTH. In tis (N  7), miscellaneous nephropathies (N  5), and
unknown origin (N  1). HD patients were dialyzedthyroparathyroidectomized rats, the administration of
human PTH-(7-84) alone or in a mixture of other C-PTH three times a week for three or four hours. Patients on
CAPD underwent four to five 2 to 2.5 L exchanges perfragments such as PTH-(39-84) and PTH-(53-84) antago-
nized the calcemic response elicited by PTH-(1-84) day. Calcium dialysate was 2.5 mEq/L. Only routine dial-
ysis support medications were given, including calcium[24, 25]. Moreover, several binding studies have demon-
strated the presence of C-PTH receptors in kidney and salts for phosphate binding.
bone cells [13, 25–31], especially in osteocytes [31].
ProtocolBecause the large C-PTH fragments contain portions
of PTH essential for binding to either the PTH-1 receptor After signing the consent form, patients were sched-
uled to undergo an iliac crest bone biopsy. Before bone[24, 32–36] or the C-PTH receptor [13, 25–31], the large
C-PTH fragments have the potential to antagonize PTH- biopsy, patients received double tetracycline labeling of
bone as previously described [37]. During the week be-(1-84) action on bone.
In the present study, we assume that endogenous fore bone biopsies, on days when bone labels were not
administered, blood samples were obtained after a 12-C-PTH fragments in blood of patients on dialysis are
antagonists of the effects of PTH-(1-84) on bone turn- hour fast for measurement of circulating calcium, phos-
phorus, intact PTH, PTH-(1-84), bone-specific alkalineover. We hypothesize that the C-PTH fragments act as
a negative biologic regulator of the stimulatory effects phosphatase (BSAP), and osteocalcin levels. In a subset
of six patients, two to four weeks after the bone biopsy,of PTH-(1-84) on bone turnover, and thus, the PTH-(1-
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in vivo dynamic tests of parathyroid gland function, that ments were determined by subtracting the PTH-(1-84)
circulating levels from the results of the intact PTH. Theis, effects of hypercalcemia on PTH peptides, were per-
formed. PTH-(1-84)/C-PTH fragments ratio was then calculated.
Serum osteocalcin levels were measured with the IRMA
Bone biopsy, mineralized bone histology, and Human Osteocalcin 100T kit (Nichols Institute Diagnos-
bone histomorphometry tics). The reference range was 2.0 to 10.0 ng/mL. The
intra-assay and interassay variations were 5.3 and 5.7%,Anterior iliac crest bone biopsies were done under
local anesthesia and conscious sedation. Bone samples respectively. Serum BSAP levels were determined using
an IRMA assay (Tandem-R Ostase; Hybritech, Sanwere obtained with the one-step electrical drill technique
(Straumann Medical, Waldenburg, Switzerland) as pre- Diego, CA, USA). Reference ranges are 3.9 to 20.9 g/L
for men and 2.9 to 20.1 g/L for women. The intra-viously described [37].
Bone samples were processed undecalcified as pre- assay and interassay coefficients of variation were 6.7
and 8.1%, respectively.viously described [38]. Sections were stained with the
modified Masson-Goldner trichrome stain [39], the aurin
Statistical analysistricarboxylic acid stain [40], and solochrome azurin [41].
Unstained sections were prepared for phase contrast and Patients were classified as having high or normal bone
turnover if activation frequency was above the lowerfluorescent light microscopy.
Histomorphometric analysis of bone was done at stan- limit of reference range obtained from bone samples of
normal age- and gender-matched volunteers processeddardized sites in cancellous bone using the semiauto-
matic method (Osteoplan II; Kontron, Munich, Ger- and analyzed in our laboratory (0.42 year	1). In the
same manner, patients were classified as having low bonemany) at a magnification of 
200 [42, 43]. Activation
frequency a parameter, which includes both bone forma- turnover if activation frequency was below 0.42 year	1.
Results are expressed as mean  SEM. All statisticaltion and resorption, was measured for determination of
bone turnover. In the present study, there was a strong tests were two sided. An assigned significance level of
0.05 was used. Normality of distribution was assessed byrelationship between activation frequency and bone for-
mation rate/bone surface (BFR/BS; r 0.96, P 0.001). the Lilliefors test, and homogeneity of variance was
tested with the Levene test. Adequate transformations
Induction of hypercalcemia of the data were done for serum calcium (reciprocal)
and plasma intact PTH (square root) [45]. ComparisonsSerum calcium was raised during a two-hour infusion
of 10% calcium gluconate (9.3 mg Ca2/mL) according of continuous values between bone turnover groups were
performed by the Student t test. The chi-square testto the method of Ramirez et al [44]. The initial dose of
calcium was 2 mg/kg · hour and was increased thereafter was used for categorical variables. Comparisons between
results of CAPD and HD patients were done using theby 1 mg/kg · hour every 20 minutes. Blood was collected
30, 15, and 0 minutes before infusion and every 10 min- Student t test. Pearson’s coefficients of correlation were
obtained between activation frequency and demographicutes thereafter for determinations of serum ionized cal-
cium, intact PTH levels, and plasma PTH-(1-84) concen- and biochemical variables. Logistic regression was per-
formed to detect predictive factors of activation fre-trations.
quency. Computations and analyses were performed us-
Biochemistry ing SPSS 7.5 software package for Windows (SPSS Inc.,
Chicago, IL, USA).Serum calcium and phosphorus were measured by
standard laboratory techniques. Ionized calcium was de- Post-test probability parameters (sensitivity, specificity,
predictive value positive and negative), receiver-operatortermined using a Radiometer Copenhagen (Westlake,
OH, USA). Plasma intact PTH levels were determined characteristics (ROC) curves, and areas under the curves
were obtained using Analyse-It software for Microsoftwith the IRMA assay for intact PTH (Nichols Institute
Diagnostics, San Juan Capistrano, CA, USA). The refer- Excel, version 1.5 (Analyse-It Software, LTD, Leeds,
UK). ROC curves are a plot of the true positive rateence range is 15 to 65 pg/mL. The intra-assay and in-
terassay coefficients of variation were 3.4 and 5.6%, re- (sensitivity) against false positive rate (1 	 specificity),
and the area under the curve is a measure of test accu-spectively. Plasma PTH-(1-84) was determined with the
IRMA assay using a radiolabeled detection antibody racy. Comparisons between the areas under the curves
were done with the same software using the Hanleyspecific for the first amino acid from the N-terminal site
(Whole PTH; Scantibodies, Inc., Santee, CA, USA) and McNeil methods [46]. In addition, Youden indices
(sensitivity  specificity 	 1) were calculated for deter-[11, 12]. The reference range of the assay is 7 to 36 pg/mL
based on over 120 normal controls [12]. Intra-assay and mination of the best cut-off level of a biochemical param-
eter, which provides the best threshold for diagnosis ofinterassay coefficients of variation were 5 and 7%,
respectively. Plasma concentrations of the C-PTH frag- a disease, in the present study low bone turnover [47].
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Table 1. Demographics, clinical, and biochemical characteristics of
51 chronically dialyzed patients according to levels of
bone turnover
Low bone High or normal
turnover bone turnover
Number of patients 28 23
Age years 503 393a
Patients on HD/CAPD 16/12 16/7
Male/female 18/10 11/12
Diabetic patients 8/20 4/18
Duration on dialysis months 264 254
Serum calcium mg/dL 9.30.2 9.00.2
Ionized calcium mEq/L 4.850.11 4.700.08
Serum phosphorus mg/dL 6.10.4 7.10.5
Serum bone-specific alkaline
phosphatase lg/L 19.83.45 35.14.39a
Serum osteocalcin ng/mL 21.54.8 34.55.1
Fig. 1. Mean values of intact parathyroid hormone (PTH), parathyroid
Abbreviations are: HD, hemodialysis; CAPD, chronic ambulatory peritoneal hormone (1-84) [PTH-(1-84)], and large carboxyterminal-PTH (C-PTH)
dialysis. fragments (C-PTH fragments) in 51 patients on chronic maintenancea Different from low bone turnover, P  0.01, student t test
dialysis with low bone turnover ( ) and high or normal bone turnover
( ). The asterisk indicates significant differences between high or nor-
mal and low bone turnover (P  0.01).
RESULTS
Bone turnover in the studied patients
More than half of the patients exhibited low bone
turnover, whereas high or normal bone turnover was
found in approximately 45% (Table 1). None of the bone
samples exhibited stainable aluminum deposits. Patients
with low bone turnover were older than those with high
or normal bone turnover (Table 1). Low bone turnover
also was found more frequently in diabetics and patients
on CAPD; however, this did not reach statistical signifi-
cance (Table 1). There were no differences in gender
distribution, age, number of diabetic patients, duration
on dialysis, or biochemical and hormonal parameters
between patients on HD and CAPD.
Fig. 2. Mean value of the PTH-(1-84)/C-PTH fragments ratio in 51
patients on chronic maintenance dialysis with low bone turnover (lowBiochemical and hormonal parameters
BT) and high or normal bone turnover (high-N BT). The asterisk
Serum calcium and phosphorus levels were similar in indicates significant difference between high or normal and low bone
turnover (P  0.01).patients with various levels of bone turnover (Table 1).
Serum BSAP levels were significantly higher in patients
with high or normal than low bone turnover (Table 1).
Higher serum osteocalcin levels were associated with Relationship between blood indices and bone turnover
high or normal bone turnover; however, this did not
Relationships between plasma intact PTH, PTH-(1-84),
reach statistical significance (Table 1). Both plasma in- PTH-(1-84)/C-PTH fragments, and BSAP and activation
tact and PTH-(1-84) were significantly higher in patients frequency (bone turnover) are shown in Figure 3. PTH-
with high or normal than low bone turnover, whereas (1-84) and PTH-(1-84)/C-PTH fragment ratio correlated
the calculated C-PTH fragments were similar (Fig. 1). best with activation frequency (r  0.73 and 0.68, P 
Patients with low bone turnover had significantly more 0.01, respectively), whereas intact PTH, osteocalcin, and
C-PTH fragments than PTH-(1-84) (P 0.001), whereas BSAP had somewhat lower coefficients of correlation
patients with high or normal bone turnover had signifi- (0.51, 0.48, and 0.42, P 0.01, respectively). Serum total
cantly more PTH-(1-84) than C-PTH fragments (P  and ionized calcium and phosphorus did not correlate
0.001; Fig. 1), and the PTH-(1-84)/C-PTH fragment ratio with any of the PTH peptides, BSAP, or osteocalcin. All
was significantly higher in patients with high or normal data obtained using BFR/BS as end point yielded results
(range of 0.47 to 14.2) than low bone turnover (range comparable to those obtained with activation frequency.
The PTH-(1-84) levels showed the best relationshipof 0.01 to 0.99; Fig. 2).
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Fig. 3. Relationships between intact PTH, PTH-(1-84), PTH-(1-84)/C-PTH fragment ratio, and bone-specific alkaline phosphatase and bone
turnover (activation frequency) in 51 patients on chronic maintenance dialysis.
with bone turnover; however, correlations are driven, at 0.05), intact PTH (P  0.01), and osteocalcin (P  0.01;
least in part, by the extreme values, whereas the pre- Fig. 5). The area under the curve was also significantly
dictive value of a test is determined by the distribution greater for PTH-(1-84) than for intact PTH and osteocal-
of the intermediate values (slope). cin (P  0.05; Fig. 5). There was no difference between
BSAP, osteocalcin, and intact PTH (Fig. 5).
Determination of the best predictor of bone turnover
To determine the factor(s) that predicts bone turn-
Determination of the best cut-off pointover, we performed logistic regression and post-test
probability. To determine the best cut-off level of the PTH-(1-84)/
Logistic regression pointed to the PTH-(1-84)/C-PTH C-PTH fragment ratio, the Youden indices for the PTH-
fragments ratio as the only parameter predicting bone (1-84)/C-PTH fragment ratio were calculated for every
turnover (activation frequency, Ac.f, P  0.001) with an level of the ratio. Given that a perfect cut-off would have
overall predictability of 88.2%. a Youden index of 1, the highest Youden index (0.826)
was found for a value of PTH-(1-84)/C-PTH fragment
Ac.f 
1
1  e	(	5.25.5 ratio)
ratio of 1 (Fig. 6).
To test how this cut-off point discriminates between
levels of bone turnover, we determined the number ofPost-test probability parameters for the PTH-(1-84)/
patients correctly diagnosed with a PTH-(1-84)/C-PTHC-PTH fragment ratio to predict low bone turnover are
fragment ratio above or below 1 (Fig. 3). All 19 patientsshown in Table 2. Their composite results, that is, the
with a PTH-(1-84)/C-PTH fragment ratio above 1 hadROC curves for PTH-(1-84)/C-PTH fragments ratio as
normal or high bone turnover. The 32 patients with awell as for PTH-(1-84), intact PTH, BSAP, and osteocal-
ratio less than 1 exhibited low bone turnover except incin are shown in Figure 4. The area under the curve for
4 patients who had either normal (N  2) or high bonethe PTH-(1-84)/C-PTH fragment ratio was significantly
greater than those of PTH-(1-84) (P 0.05), BSAP (P turnover (N  2). No other parameters, alone or in
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Fig. 4. Receiver-operator characteristics (ROC)
curves for the prediction of bone turnover in
chronically dialyzed patients. (A) Symbols are:
plasma PTH-(1-84)/C-PTH fragment ratio
(), plasma PTH-(1-84) (), and plasma intact
PTH (). (B) Symbols are: serum bone-spe-
cific alkaline phosphatase () and serum os-
teocalcin ().
Fig. 5. Area under the curve (AUC) of the receiver-operator charac-
teristics (ROC) curves for PTH-(1-84)/C-PTH fragments ratio, PTH-
(1-84), bone-specific alkaline phosphatase (BSAP), intact PTH, and os-
teocalcin (OC). Values with the same letter are not significantly different. Fig. 6. Youden indices for determination of the optimal cut-off level of
the PTH-(1-84)/C-PTH fragments ratio for prediction of bone turnover.
Table 2. Post-test probability of PTH-(1-84)/C-PTH fragments PTH
ratio for prediction of low bone turnover
Effects of hypercalcemia on the PTH-(1-84)/C-PTH
Sens Spec PVP PVN
fragments ratioPTH-(1-84)/C-PTH
fragments %
Induction of hypercalcemia by infusion of calcium glu-
0.3 35.7 100 100 56.1
conate in six patients resulted in the progressive decrease0.4 39.2 100 100 57.5
0.5 46.4 95.6 92.8 59.5 in intact PTH, PTH-(1-84), as well as the PTH-(1-84)/
0.6 67.8 91.3 90.5 70.0 C-PTH fragment ratio with time (Fig. 7). Moreover,
0.7 75.0 86.9 87.7 74.1
there was an inverse relationship between serum-ionized0.8 78.6 86.9 88.0 76.9
0.9 89.3 86.9 89.3 86.9 calcium levels and the PTH-(1-84)/C-PTH fragment ratio
1.0 100 82.6 87.5 100 in individual patients (Fig. 8).
1.1 100 82.6 87.5 100
1.2 100 69.5 80.0 100
Abbreviations are: Sens, sensitivity; Spec, specificity; PVP, predictive value DISCUSSION
for positive results; PVN, predictive value for negative results.
The novel information provided by the present study
is the superiority of the PTH-(1-84)/C-PTH fragment
ratio in predicting bone turnover compared with all othercombination, including serum calcium, identified these
four patients. When patients with blood intact PTH lev- biochemical parameters, alone or in combination, thus
supporting our central hypothesis. Bone turnover is re-els between 100 and 500 pg/mL were analyzed separately,
a PTH-(1-84)/C-PTH fragment ratio 1 was also 100% flected by the balance between the relative amount of
circulating PTH-(1-84) and large C-PTH fragments. Pre-diagnostic for high or normal bone turnover, whereas a
ratio 1 was 82% diagnostic for low bone turnover. dominance of circulating active PTH-(1-84) over the
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Fig. 7. Changes in PTH peptides during a
two-hour calcium gluconate infusion in six pa-
tients on dialysis. (A) Plasma PTH-(1-84) ()
and intact PTH (). (B) PTH-(1-84)/C-PTH
fragment ratio.
eral fragments, one can assume that 7-84 PTH is the
major antagonist since it was shown to be by far the
most potent antagonist among all tested PTH fragments
[25]. The remaining scatter between the PTH-(1-84)/
C-PTH fragment ratio and bone turnover could be re-
lated to different target organ responses at the receptor
or post-receptor levels to given levels of PTH.
The mechanism(s) by which the large C-PTH frag-
ments may antagonize the effect of PTH-(1-84) on bone
is unclear. It has been speculated that this large amino-
terminally truncated fragment (most likely 7-84 PTH)
may act as competitive antagonist or regulate the expres-
sion or sensitivity of the PTH receptors [11]. Although
the 7-34 PTH fragment (which is part of 7-84 PTH) has
a binding domain to PTH-1R [48, 49], it is still a poor
competitor of 1-34 PTH (which is the active sequence
of PTH) for the PTH-1R [32, 33]. This finding renders
it unlikely that the antagonistic action of 7-84 PTH on
bone effects of PTH-(1-84) is mediated through the PTH-
1R. Evidence is accumulating for the expression of func-
tional C-terminal receptors from studies in a variety of
skeletally derived cells [13, 18, 25–31]. The basic residues
Arg25 and Lys 53 have been recently reported to beFig. 8. Relationship between ionized calcium levels and PTH-(1-84)/
C-PTH fragments ratio in a patients on dialysis during calcium gluconate critical for effective interaction of PTH-(1-84) with re-
infusion. ceptors for C-terminal portions of PTH-(1-84) [31]. Fur-
ther studies are needed to elucidate the precise mode of
action of the large C-PTH fragments on bone, in particu-C-PTH fragments is associated with increased bone turn-
lar if the C-PTH fragments interacts with the PTH-1R,over, whereas predominance of C-PTH fragments over
the C-terminal PTH receptor, or another receptor.PTH-(1-84) is most often associated with low bone turn-
Another clinically relevant question concerns the fac-over. The present data lend support to the notion of an
tors that regulate the relative production of PTH-(1-84)antagonistic effect of the C-PTH fragments on PTH-(1-
and large C-PTH fragments by parathyroid glands. Pre-84) action on bone, and extend preclinical observations
vailing serum calcium levels at time of blood sampling[24, 32–36] to the dialysis population. The wide range of
did not have an impact on the diagnostic value of thethe obtained results in the PTH-(1-84)/C-PTH fragment
different PTH peptides. This might be due to the cross-ratio (from 0.01 to 14.2) demonstrates that a simple fixed
sectional design of the study and more certainly to thepercentage of intact PTH cannot be identified for predic-
various degrees of hyperplasia and/or calcium sensitivitytion of the large C-PTH fragments. Even though it is
likely that the calculated C-PTH fragments contains sev- of the parathyroid glands in the studied patients ex-
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2. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormoneplaining that comparable calcium levels are often ob-
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served at different PTH levels [50]. However, our present osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–
150, 1992study demonstrates that changes in serum calcium act
3. Salusky IB, Goodman WG: In vivo studies of parathyroid glandas regulators of the relative amount of circulating PTH-
function in secondary hyperparathyroidism. Adv Nephrol Necker
(1-84) and C-PTH fragments. These data extend the Hosp 25:289–302, 1996
4. Couttenye MM, D’Haese PC, Van Hoof VO, et al: Low serumresults of a recent study that demonstrated that plasma
levels of alkaline phosphatase of bone origin: A good marker oflevels of PTH-(1-84) decreased more readily than intact
adynamic bone disease in haemodialysis patients. Nephrol Dial
PTH with calcium infusion [11]. This is also in agreement Transplant 11:1065–1072, 1996
5. Wang M, Hercz G, Sherrard DJ, et al: Relationship betweenwith previous in vitro and in vivo studies that showed that
intact 1-84 parathyroid hormone and bone histomorphometric pa-bovine parathyroid glands incubated in hypocalcemic
rameters in dialysis patients without aluminum toxicity. Am J Kid-
medium almost exclusively secrete PTH-(1-84), whereas ney Dis 26:836–844, 1995
6. Qi Q, Monier-Faugere MC, Geng Z, et al: Predictive value ofexposure to hypercalcemic medium results in mostly de-
serum parathyroid hormone levels for bone turnover in patientsgraded PTH [51–58]. Taken together, these data suggest
on chronic maintenance dialysis. Am J Kidney Dis 26:622–631,
that in ESRD patients receiving high doses of calcium 1995
7. Coen G, Ballanti P, Bonucci E, et al: Bone markers in the diagno-on a daily basis, the balance between PTH-(1-84) and
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Nephrol Dial Transplant 13:2294–2302, 1998
of the C-PTH fragments, which may result in blunting 8. Malluche HH, Monier-Faugere MC: Understanding and manag-
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